Skip to main content
Top
Published in: Diabetology & Metabolic Syndrome 1/2010

Open Access 01-12-2010 | Review

Combination therapy in hypertension: An update

Authors: Sanjay Kalra, Bharti Kalra, Navneet Agrawal

Published in: Diabetology & Metabolic Syndrome | Issue 1/2010

Login to get access

Abstract

Meticulous control of blood pressure is required in patients with hypertension to produce the maximum reduction in clinical cardiovascular end points, especially in patients with comorbidities like diabetes mellitus where more aggressive blood pressure lowering might be beneficial. Recent clinical trials suggest that the approach of using monotherapy for the control of hypertension is not likely to be successful in most patients. Combination therapy may be theoretically favored by the fact that multiple factors contribute to hypertension, and achieving control of blood pressure with single agent acting through one particular mechanism may not be possible. Regimens can either be fixed dose combinations or drugs added sequentially one after other. Combining the drugs makes them available in a convenient dosing format, lower the dose of individual component, thus, reducing the side effects and improving compliance. Classes of antihypertensive agents which have been commonly used are angiotensin receptor blockers, thiazide diuretics, beta and alpha blockers, calcium antagonists and angiotensin-converting enzyme inhibitors. Thiazide diuretics and calcium channel blockers are effective, as well as combinations that include renin-angiotensin-aldosterone system blockers, in reducing BP. The majority of currently available fixed-dose combinations are diuretic-based. Combinations may be individualized according to the presence of comorbidities like diabetes mellitus, chronic renal failure, heart failure, thyroid disorders and for special population groups like elderly and pregnant females.
Literature
1.
go back to reference American Diabetes Association: Standards of medical care in diabetes. Diabetes Care. 2010, 33 (Suppl 1): 11-61.CrossRef American Diabetes Association: Standards of medical care in diabetes. Diabetes Care. 2010, 33 (Suppl 1): 11-61.CrossRef
2.
go back to reference Ong KL, Cheung BM, Man YB, Lau CP, Lam KS: Prevalence, awareness, treatment, and control of hypertension among United States adults 1999-2004. Hypertension. 2007, 49: 69-75. 10.1161/01.HYP.0000252676.46043.18.CrossRefPubMed Ong KL, Cheung BM, Man YB, Lau CP, Lam KS: Prevalence, awareness, treatment, and control of hypertension among United States adults 1999-2004. Hypertension. 2007, 49: 69-75. 10.1161/01.HYP.0000252676.46043.18.CrossRefPubMed
3.
go back to reference Lewington S, Clarke R, Qizilbash N, Peto R, Collins R, for the Prospective Studies Collaboration: Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002, 360: 1903-1913. 10.1016/S0140-6736(02)11911-8.CrossRefPubMed Lewington S, Clarke R, Qizilbash N, Peto R, Collins R, for the Prospective Studies Collaboration: Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002, 360: 1903-1913. 10.1016/S0140-6736(02)11911-8.CrossRefPubMed
4.
go back to reference Hansson L, Zanchetti A, Carruthers SG, Dahlöf B, Elmfeldt D, Julius S, Ménard J, Rahn KH, Wedel H, Westerling S: Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial. Lancet. 1998, 351: 1755-1762. 10.1016/S0140-6736(98)04311-6.CrossRefPubMed Hansson L, Zanchetti A, Carruthers SG, Dahlöf B, Elmfeldt D, Julius S, Ménard J, Rahn KH, Wedel H, Westerling S: Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial. Lancet. 1998, 351: 1755-1762. 10.1016/S0140-6736(98)04311-6.CrossRefPubMed
5.
go back to reference Cook NR, Cohen J, Hebert PR, Taylor JO, Hennekens CH: Implications of small reductions in diastolic blood pressure for primary prevention. Arch Intern Med. 1995, 155: 701-709. 10.1001/archinte.155.7.701.CrossRefPubMed Cook NR, Cohen J, Hebert PR, Taylor JO, Hennekens CH: Implications of small reductions in diastolic blood pressure for primary prevention. Arch Intern Med. 1995, 155: 701-709. 10.1001/archinte.155.7.701.CrossRefPubMed
6.
go back to reference Norris K, Neutel JM: Emerging Insights in the First-Step Use of Antihypertensive Combination Therapy. J Clin Hypertens (Greenwich). 2007, 9 (12 Suppl 5): 5-14. 10.1111/j.1524-6175.2007.07807.x.CrossRef Norris K, Neutel JM: Emerging Insights in the First-Step Use of Antihypertensive Combination Therapy. J Clin Hypertens (Greenwich). 2007, 9 (12 Suppl 5): 5-14. 10.1111/j.1524-6175.2007.07807.x.CrossRef
7.
go back to reference Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003, 42: 1206-1252. 10.1161/01.HYP.0000107251.49515.c2. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003, 42: 1206-1252. 10.1161/01.HYP.0000107251.49515.c2.
8.
go back to reference European Society of Hypertension-European Society of Cardiology Guidelines Committee. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens. 2003, 21: 1011-1053. 10.1097/00004872-200306000-00001. European Society of Hypertension-European Society of Cardiology Guidelines Committee. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens. 2003, 21: 1011-1053. 10.1097/00004872-200306000-00001.
9.
go back to reference Moser M, Franklin SS: Hypertension management: results of a new national survey for the hypertension education foundation: Harris interactive. J Clin Hypertens (Greenwich). 2007, 9: 316-323. 10.1111/j.1524-6175.2007.07152.x.CrossRef Moser M, Franklin SS: Hypertension management: results of a new national survey for the hypertension education foundation: Harris interactive. J Clin Hypertens (Greenwich). 2007, 9: 316-323. 10.1111/j.1524-6175.2007.07152.x.CrossRef
10.
go back to reference Dunlay MC, Fitzpatrick V, Chrysant S, Francischetti EA, Goldberg AI, Sweet CS: Losartan potassium as initial therapy in patients with severe hypertension. J Hum Hypertens. 1995, 9: 861-867.PubMed Dunlay MC, Fitzpatrick V, Chrysant S, Francischetti EA, Goldberg AI, Sweet CS: Losartan potassium as initial therapy in patients with severe hypertension. J Hum Hypertens. 1995, 9: 861-867.PubMed
11.
go back to reference Oparil S, Ripley E, on behalf of Candesartan Study Investigators: Candesartan cilexetil enhances blood pressure reduction severe (state 3, JNC-VI) hypertensive patients inadequately controlled with HCTZ. Am J Hypertens. 1998, 11 (4 part 1): 121A-10.1016/S0895-7061(97)91163-8.CrossRef Oparil S, Ripley E, on behalf of Candesartan Study Investigators: Candesartan cilexetil enhances blood pressure reduction severe (state 3, JNC-VI) hypertensive patients inadequately controlled with HCTZ. Am J Hypertens. 1998, 11 (4 part 1): 121A-10.1016/S0895-7061(97)91163-8.CrossRef
12.
go back to reference Larochelle P, Flack JM, Marbury TC, Sareli P, Krieger EM, Reeves RA, for the Irbesartan Multicenter Investigators: Effects and tolerability of irbesartan versus enalapril in patients with severe hypertension. Am J Cardiol. 1997, 80: 1613-1615. 10.1016/S0002-9149(97)00784-4.CrossRefPubMed Larochelle P, Flack JM, Marbury TC, Sareli P, Krieger EM, Reeves RA, for the Irbesartan Multicenter Investigators: Effects and tolerability of irbesartan versus enalapril in patients with severe hypertension. Am J Cardiol. 1997, 80: 1613-1615. 10.1016/S0002-9149(97)00784-4.CrossRefPubMed
13.
go back to reference Cifkova R, Peleska J, Hradec J, Pintérová E, Zeman K, Oddou-Stock P, Thirlwell J, Botteri F: Valsartan and atenolol in patients with severe essential hypertension. J Hum Hypertens. 1998, 12: 563-567. 10.1038/sj.jhh.1000615.CrossRefPubMed Cifkova R, Peleska J, Hradec J, Pintérová E, Zeman K, Oddou-Stock P, Thirlwell J, Botteri F: Valsartan and atenolol in patients with severe essential hypertension. J Hum Hypertens. 1998, 12: 563-567. 10.1038/sj.jhh.1000615.CrossRefPubMed
14.
go back to reference Hansson L, Zanchetti A, Carruthers SG, Dahlöf B, Elmfeldt D, Julius S, Ménard J, Rahn KH, Wedel H, Westerling S, for the HOT Study Group: Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet. 1998, 351: 1755-1762. 10.1016/S0140-6736(98)04311-6.CrossRefPubMed Hansson L, Zanchetti A, Carruthers SG, Dahlöf B, Elmfeldt D, Julius S, Ménard J, Rahn KH, Wedel H, Westerling S, for the HOT Study Group: Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet. 1998, 351: 1755-1762. 10.1016/S0140-6736(98)04311-6.CrossRefPubMed
15.
go back to reference Littlejohn TW, Majul CR, Olvera R, Seeber M, Kobe M, Guthrie R, Oigman W: Results of Treatment With Telmisartan-Amlodipine in Hypertensive Patients. The journal of clinical hypertension. 2009, 11: 207-213. 10.1111/j.1751-7176.2009.00098.x.CrossRefPubMed Littlejohn TW, Majul CR, Olvera R, Seeber M, Kobe M, Guthrie R, Oigman W: Results of Treatment With Telmisartan-Amlodipine in Hypertensive Patients. The journal of clinical hypertension. 2009, 11: 207-213. 10.1111/j.1751-7176.2009.00098.x.CrossRefPubMed
16.
go back to reference Sanford M, Keam SJ: Olmesartan medoxomil/amlodipine. Drugs. 2009, 69: 717-729. 10.2165/00003495-200969060-00005.CrossRefPubMed Sanford M, Keam SJ: Olmesartan medoxomil/amlodipine. Drugs. 2009, 69: 717-729. 10.2165/00003495-200969060-00005.CrossRefPubMed
17.
go back to reference Hoffmann J: Comparison of a felodipine-metoprolol combination tablet vs each component alone as antihypertensive therapy. The German Multicentre Study Group. Blood Press Suppl. 1993, 1: 30-36.PubMed Hoffmann J: Comparison of a felodipine-metoprolol combination tablet vs each component alone as antihypertensive therapy. The German Multicentre Study Group. Blood Press Suppl. 1993, 1: 30-36.PubMed
18.
go back to reference Ishimitsu T, Yagi S, Ebihara A, Doi Y, Domae A, Shibata A, Kimura M, Sugishita Y, Sagara E, Sakamaki T, Murata K: Long-term evaluation of combined antihypertensive therapy with lisinopril and a thiazide diuretic in patients with essential hypertension. Jpn Heart J. 1997, 38: 831-840.CrossRefPubMed Ishimitsu T, Yagi S, Ebihara A, Doi Y, Domae A, Shibata A, Kimura M, Sugishita Y, Sagara E, Sakamaki T, Murata K: Long-term evaluation of combined antihypertensive therapy with lisinopril and a thiazide diuretic in patients with essential hypertension. Jpn Heart J. 1997, 38: 831-840.CrossRefPubMed
19.
go back to reference Mansia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, Grassi G, Heagerty AM, Kjeldsen SE, Laurent S, Narkiewicz K, Ruilope L, Rynkiewicz A, Schmieder RE, Struijker Boudier HA, Zanchetti A: 2007 ESH-ESC Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Blood Press. 2007, 16: 135-232. 10.1080/08037050701461084.CrossRefPubMed Mansia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, Grassi G, Heagerty AM, Kjeldsen SE, Laurent S, Narkiewicz K, Ruilope L, Rynkiewicz A, Schmieder RE, Struijker Boudier HA, Zanchetti A: 2007 ESH-ESC Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Blood Press. 2007, 16: 135-232. 10.1080/08037050701461084.CrossRefPubMed
20.
go back to reference Weir MR, Bakris GL: Combination Therapy With Renin-Angiotensin-Aldosterone Receptor Blockers for Hypertension: How Far Have We Come?. J Clin Hypertens (Greenwich). 2008, 10: 146-152. 10.1111/j.1751-7176.2008.07439.x.CrossRef Weir MR, Bakris GL: Combination Therapy With Renin-Angiotensin-Aldosterone Receptor Blockers for Hypertension: How Far Have We Come?. J Clin Hypertens (Greenwich). 2008, 10: 146-152. 10.1111/j.1751-7176.2008.07439.x.CrossRef
21.
go back to reference Grossman E, Messerli FH, Goldbourt U: Does diuretic therapy increase the risk of renal cell carcinoma?. Am J Cardiol. 1999, 83: 1090-1093. 10.1016/S0002-9149(99)00021-1.CrossRefPubMed Grossman E, Messerli FH, Goldbourt U: Does diuretic therapy increase the risk of renal cell carcinoma?. Am J Cardiol. 1999, 83: 1090-1093. 10.1016/S0002-9149(99)00021-1.CrossRefPubMed
22.
go back to reference Messerli FH, Grossman E: Beta-Blockers and Diuretics: To Use or Not to Use. Am J Hypertens. 1999, 12 (Pt 1-2): 157S-163S. 10.1016/S0895-7061(99)00220-4.CrossRefPubMed Messerli FH, Grossman E: Beta-Blockers and Diuretics: To Use or Not to Use. Am J Hypertens. 1999, 12 (Pt 1-2): 157S-163S. 10.1016/S0895-7061(99)00220-4.CrossRefPubMed
23.
go back to reference Warmack TS, Estes MA, Heldenbrand S, Franks AM: Beta-adrenergic antagonists in hypertension: a review of the evidence. Ann Pharmacother. 2009, 43: 2031-2043. 10.1345/aph.1M381.CrossRefPubMed Warmack TS, Estes MA, Heldenbrand S, Franks AM: Beta-adrenergic antagonists in hypertension: a review of the evidence. Ann Pharmacother. 2009, 43: 2031-2043. 10.1345/aph.1M381.CrossRefPubMed
24.
go back to reference Poulter NR, Dobson JE, Sever PS, Dahlöf B, Wedel H, Campbell NR: Baseline heart rate, antihypertensive treatment, and prevention of cardiovascular outcomes in ASCOT (Anglo-Scandinavian Cardiac Outcomes Trial). J Am Coll Cardiol. 2009, 54: 1154-1161. 10.1016/j.jacc.2009.04.087.CrossRefPubMed Poulter NR, Dobson JE, Sever PS, Dahlöf B, Wedel H, Campbell NR: Baseline heart rate, antihypertensive treatment, and prevention of cardiovascular outcomes in ASCOT (Anglo-Scandinavian Cardiac Outcomes Trial). J Am Coll Cardiol. 2009, 54: 1154-1161. 10.1016/j.jacc.2009.04.087.CrossRefPubMed
25.
go back to reference Hoes AW, Grobbee DE, Lubsen J, Man in'tVeld AJ, van der Does E, Hofman A: Diuretics, b-blockers, and the risk for sudden cardiac death in hypertensive patients. Ann Intern Med. 1995, 123: 482-487.CrossRef Hoes AW, Grobbee DE, Lubsen J, Man in'tVeld AJ, van der Does E, Hofman A: Diuretics, b-blockers, and the risk for sudden cardiac death in hypertensive patients. Ann Intern Med. 1995, 123: 482-487.CrossRef
26.
go back to reference Brown CL, Backhouse CI, Grippat JC, Santoni JP: The effect of perindopril and hydrochlorothiazide alone and in combination on blood pressure and on the renin-angiotensin system in hypertensive subjects. Eur J Clin Pharmacol. 1990, 39: 327-332. 10.1007/BF00315404.CrossRefPubMed Brown CL, Backhouse CI, Grippat JC, Santoni JP: The effect of perindopril and hydrochlorothiazide alone and in combination on blood pressure and on the renin-angiotensin system in hypertensive subjects. Eur J Clin Pharmacol. 1990, 39: 327-332. 10.1007/BF00315404.CrossRefPubMed
27.
go back to reference Chrysant SG: Antihypertensive effectiveness of low-dose lisinopril-hydrochlorothiazide combination: a large multicenter study. Lisinopril-Hydrochlorothiazide Group. Arch Intern Med. 1994, 154: 737-743. 10.1001/archinte.154.7.737.CrossRefPubMed Chrysant SG: Antihypertensive effectiveness of low-dose lisinopril-hydrochlorothiazide combination: a large multicenter study. Lisinopril-Hydrochlorothiazide Group. Arch Intern Med. 1994, 154: 737-743. 10.1001/archinte.154.7.737.CrossRefPubMed
28.
go back to reference Efficacy and safety of fixed combination of perindopril and indapamide in type 2 diabetes: results from ADVANCE in context of available evidence. J Hypertens. 2008, 26 (Suppl 3): 23S-30S. 10.1097/01.hjh.0000334603.78628.33. Efficacy and safety of fixed combination of perindopril and indapamide in type 2 diabetes: results from ADVANCE in context of available evidence. J Hypertens. 2008, 26 (Suppl 3): 23S-30S. 10.1097/01.hjh.0000334603.78628.33.
29.
go back to reference Rosenstock J, Rossi l, Lin CS, MacNeil D, Osbakken M: The effects of irbesartan added to hydrochlorothiazide for the treatment of hypertension in patients non-responsive to hydrochlorothiazide alone. J Clin Pharm Ther. 1998, 23: 433-440. 10.1046/j.1365-2710.1998.00184.x.CrossRefPubMed Rosenstock J, Rossi l, Lin CS, MacNeil D, Osbakken M: The effects of irbesartan added to hydrochlorothiazide for the treatment of hypertension in patients non-responsive to hydrochlorothiazide alone. J Clin Pharm Ther. 1998, 23: 433-440. 10.1046/j.1365-2710.1998.00184.x.CrossRefPubMed
30.
go back to reference Neutel JM, Franklin SS, Oparil S, Bhaumik A, Ptaszynska A, Lapuerta P: Efficacy and safety of irbesartan/HcTZ combination therapy as initial treatment for rapid control of severe hypertension. J Clin Hypertens (Greenwich). 2006, 8: 850-857. 10.1111/j.1524-6175.2006.05676.x.CrossRef Neutel JM, Franklin SS, Oparil S, Bhaumik A, Ptaszynska A, Lapuerta P: Efficacy and safety of irbesartan/HcTZ combination therapy as initial treatment for rapid control of severe hypertension. J Clin Hypertens (Greenwich). 2006, 8: 850-857. 10.1111/j.1524-6175.2006.05676.x.CrossRef
31.
go back to reference Littlejohn T, Saini R, Kassler-Taub K, Chrysant SG, Marbury T: Long-term safety and antihypertensive efficacy of irbesartan: pooled results of five open-label studies. Clin Exp Hypertens. 1999, 21 (8): 1273-1295. 10.3109/10641969909070849.CrossRefPubMed Littlejohn T, Saini R, Kassler-Taub K, Chrysant SG, Marbury T: Long-term safety and antihypertensive efficacy of irbesartan: pooled results of five open-label studies. Clin Exp Hypertens. 1999, 21 (8): 1273-1295. 10.3109/10641969909070849.CrossRefPubMed
32.
go back to reference Reeves RA, Lin CS, Kassler-Taub K, Pouleur H: Dose-related efficacy of irbesartan for hypertension: an integrated analysis. Hypertension. 1998, 31: 1311-1316.CrossRefPubMed Reeves RA, Lin CS, Kassler-Taub K, Pouleur H: Dose-related efficacy of irbesartan for hypertension: an integrated analysis. Hypertension. 1998, 31: 1311-1316.CrossRefPubMed
33.
go back to reference Makita S, Abiko A, Naganuma Y, Tamada M, Nakamura M: Efficacy of low-dose hydrochlorothiazide in combination with telmisartan on early morning blood pressure in uncontrolled hypertensive patients. Clin Exp Hypertens. 2009, 31: 105-115. 10.1080/10641960802621259.CrossRefPubMed Makita S, Abiko A, Naganuma Y, Tamada M, Nakamura M: Efficacy of low-dose hydrochlorothiazide in combination with telmisartan on early morning blood pressure in uncontrolled hypertensive patients. Clin Exp Hypertens. 2009, 31: 105-115. 10.1080/10641960802621259.CrossRefPubMed
34.
go back to reference Ando K, Isshiki M, Takahashi K: ONgoing Evaluation of depressor effect And Safety of combination therapy with Telmisartan and low-dose hydrochlorothiazide (ONEAST)Study Group. Effect of switching from amlodipine to combination therapy with telmisartan and low-dose hydrochlorothiazide. Hypertens Res. 2009, 32: 748-752. 10.1038/hr.2009.101.CrossRefPubMed Ando K, Isshiki M, Takahashi K: ONgoing Evaluation of depressor effect And Safety of combination therapy with Telmisartan and low-dose hydrochlorothiazide (ONEAST)Study Group. Effect of switching from amlodipine to combination therapy with telmisartan and low-dose hydrochlorothiazide. Hypertens Res. 2009, 32: 748-752. 10.1038/hr.2009.101.CrossRefPubMed
35.
go back to reference Weir MR, Bakris GL: Combination therapy with Renin-Angiotensin-aldosterone receptor blockers for hypertension: how far have we come?. J Clin Hypertens (Greenwich). 2008, 10: 146-152. 10.1111/j.1751-7176.2008.07439.x.CrossRef Weir MR, Bakris GL: Combination therapy with Renin-Angiotensin-aldosterone receptor blockers for hypertension: how far have we come?. J Clin Hypertens (Greenwich). 2008, 10: 146-152. 10.1111/j.1751-7176.2008.07439.x.CrossRef
36.
go back to reference Pahor M, Psaty BM, Alderman MH, Applegate WB, Williamson JD, Furberg CD: Therapeutic benefits of ACE inhibitors and other antihypertensive drugs in patients with type 2 diabetes. Diabetes Care. 2000, 23: 888-892. 10.2337/diacare.23.7.888.CrossRefPubMed Pahor M, Psaty BM, Alderman MH, Applegate WB, Williamson JD, Furberg CD: Therapeutic benefits of ACE inhibitors and other antihypertensive drugs in patients with type 2 diabetes. Diabetes Care. 2000, 23: 888-892. 10.2337/diacare.23.7.888.CrossRefPubMed
37.
go back to reference Tatti P, Pahor M, Byington RP, Mauro PD, Guarisco R, Strollo G, Strollo F: Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET)in patients with hypertension and NIDDM. Diabetes Care. 1998, 21: 597-603. 10.2337/diacare.21.4.597.CrossRefPubMed Tatti P, Pahor M, Byington RP, Mauro PD, Guarisco R, Strollo G, Strollo F: Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET)in patients with hypertension and NIDDM. Diabetes Care. 1998, 21: 597-603. 10.2337/diacare.21.4.597.CrossRefPubMed
38.
go back to reference Nissen SE, Tuzcu EM, Libby P, Thompson PD, Ghali M, Garza D, Berman L, Shi H, Buebendorf E, Topol EJ: Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA. 2004, 292: 2217-2225. 10.1001/jama.292.18.2217.CrossRefPubMed Nissen SE, Tuzcu EM, Libby P, Thompson PD, Ghali M, Garza D, Berman L, Shi H, Buebendorf E, Topol EJ: Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA. 2004, 292: 2217-2225. 10.1001/jama.292.18.2217.CrossRefPubMed
39.
go back to reference Tobe S, Kawecka-Jaszcz K, Zannad F, Vetrovec G, Patni R, Shi H: Amlodipine Added to Quinapril vs Quinapril Alone for the Treatment of Hypertension in Diabetes: The Amlodipine in Diabetes (ANDI)Trial. J Clin Hypertens. 2007, 9: 120-127. 10.1111/j.1524-6175.2007.06949.x.CrossRef Tobe S, Kawecka-Jaszcz K, Zannad F, Vetrovec G, Patni R, Shi H: Amlodipine Added to Quinapril vs Quinapril Alone for the Treatment of Hypertension in Diabetes: The Amlodipine in Diabetes (ANDI)Trial. J Clin Hypertens. 2007, 9: 120-127. 10.1111/j.1524-6175.2007.06949.x.CrossRef
40.
go back to reference Weir MR: Targeting mechanisms of hypertensive vascular disease with dual calcium channel and renin-angiotensin system blockade. J Hum Hypertens. 2007, 21: 770-779. 10.1038/sj.jhh.1002254.CrossRefPubMed Weir MR: Targeting mechanisms of hypertensive vascular disease with dual calcium channel and renin-angiotensin system blockade. J Hum Hypertens. 2007, 21: 770-779. 10.1038/sj.jhh.1002254.CrossRefPubMed
41.
go back to reference Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, De Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H, for LIFE Study Group: Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE) a randomised trial against atenolol. Lancet. 2002, 359: 995-1003. 10.1016/S0140-6736(02)08089-3.CrossRefPubMed Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, De Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H, for LIFE Study Group: Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE) a randomised trial against atenolol. Lancet. 2002, 359: 995-1003. 10.1016/S0140-6736(02)08089-3.CrossRefPubMed
42.
go back to reference Fogari R, Derosa G, Zoppi A, Preti P, Lazzari P, Destro M, Fogari E, Rinaldi A, Mugellini A: Effect of telmisartan amlodipine combination at different doses on urinary albumin excretion in hypertensive diabetic patients with microalbuminuria. Am J Hypertens. 2007, 20: 417-422. 10.1016/j.amjhyper.2006.10.002.CrossRefPubMed Fogari R, Derosa G, Zoppi A, Preti P, Lazzari P, Destro M, Fogari E, Rinaldi A, Mugellini A: Effect of telmisartan amlodipine combination at different doses on urinary albumin excretion in hypertensive diabetic patients with microalbuminuria. Am J Hypertens. 2007, 20: 417-422. 10.1016/j.amjhyper.2006.10.002.CrossRefPubMed
43.
go back to reference Azizi M, Menard J: Combined blockade of the reninangiotensin system with angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists. Circulation. 2004, 109: 2492-2499. 10.1161/01.CIR.0000131449.94713.AD.CrossRefPubMed Azizi M, Menard J: Combined blockade of the reninangiotensin system with angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists. Circulation. 2004, 109: 2492-2499. 10.1161/01.CIR.0000131449.94713.AD.CrossRefPubMed
44.
go back to reference Mogensen CE, Neldam S, Tikkanen I, Oren S, Viskoper R, Watts RW, Cooper ME: Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes, the candesartan and lisinopril microalbuminuria (CALM)study. BMJ. 2000, 321: 1440-1444. 10.1136/bmj.321.7274.1440.PubMedCentralCrossRefPubMed Mogensen CE, Neldam S, Tikkanen I, Oren S, Viskoper R, Watts RW, Cooper ME: Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes, the candesartan and lisinopril microalbuminuria (CALM)study. BMJ. 2000, 321: 1440-1444. 10.1136/bmj.321.7274.1440.PubMedCentralCrossRefPubMed
45.
go back to reference Nakao NN, Seno H, Kasuga H, Toriyama T, Kawahara H, Fukagawa M: Effects of combination treatment with losartan and trandolapril on office and ambulatory blood pressures in non-diabetic renal disease, a CoopEraTE-abp substudy. Am J Nephrol. 2004, 24: 543-548. 10.1159/000081953.CrossRefPubMed Nakao NN, Seno H, Kasuga H, Toriyama T, Kawahara H, Fukagawa M: Effects of combination treatment with losartan and trandolapril on office and ambulatory blood pressures in non-diabetic renal disease, a CoopEraTE-abp substudy. Am J Nephrol. 2004, 24: 543-548. 10.1159/000081953.CrossRefPubMed
46.
go back to reference Nakao N, Yoshimura A, Morita H, Takada M, Kayano T, Ideura T: Combination treatment of angiotensin-ii receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE) a randomised controlled trial. Lancet. 2003, 361: 117-124. 10.1016/S0140-6736(03)12229-5.CrossRefPubMed Nakao N, Yoshimura A, Morita H, Takada M, Kayano T, Ideura T: Combination treatment of angiotensin-ii receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE) a randomised controlled trial. Lancet. 2003, 361: 117-124. 10.1016/S0140-6736(03)12229-5.CrossRefPubMed
47.
go back to reference McKelvie RS, Rouleau JL, White M, Afzal R, Young JB, Maggioni AP, Held P, Yusuf S: Comparative impact of enalapril, candesartan or metoprolol alone or in combination on ventricular remodelling in patients with congestive heart failure. Eur Heart J. 2003, 24: 1727-1734. 10.1016/S0195-668X(03)00477-9.CrossRefPubMed McKelvie RS, Rouleau JL, White M, Afzal R, Young JB, Maggioni AP, Held P, Yusuf S: Comparative impact of enalapril, candesartan or metoprolol alone or in combination on ventricular remodelling in patients with congestive heart failure. Eur Heart J. 2003, 24: 1727-1734. 10.1016/S0195-668X(03)00477-9.CrossRefPubMed
48.
go back to reference Bakris GL, Siomos M, Richardson D, Janssen I, Bolton WK, Hebert L, Agarwal R, Catanzaro D: ACE inhibitor or angiotensin receptor blockade, impact on potassium in renal failure. Kidney Int. 2000, 58: 2084-2092. 10.1111/j.1523-1755.2000.00381.x.CrossRefPubMed Bakris GL, Siomos M, Richardson D, Janssen I, Bolton WK, Hebert L, Agarwal R, Catanzaro D: ACE inhibitor or angiotensin receptor blockade, impact on potassium in renal failure. Kidney Int. 2000, 58: 2084-2092. 10.1111/j.1523-1755.2000.00381.x.CrossRefPubMed
49.
go back to reference Albitar S, Genin R, Fen-Chong M, Serveaux MO, Bourgeon B: High dose of enalapril impairs the response to erythropoietin treatment in hemodialysis patients. Nephrol Dial Transplant. 1998, 13: 1206-1210. 10.1093/ndt/13.5.1206.CrossRefPubMed Albitar S, Genin R, Fen-Chong M, Serveaux MO, Bourgeon B: High dose of enalapril impairs the response to erythropoietin treatment in hemodialysis patients. Nephrol Dial Transplant. 1998, 13: 1206-1210. 10.1093/ndt/13.5.1206.CrossRefPubMed
50.
go back to reference De Leeuw PW, Notter T, Zilles P: Comparison of different fixed antihypertensive combination drugs a double-blind, placebo controlled parallel group study. J Hypertens. 1997, 15: 87-91. 10.1097/00004872-199715010-00009.CrossRefPubMed De Leeuw PW, Notter T, Zilles P: Comparison of different fixed antihypertensive combination drugs a double-blind, placebo controlled parallel group study. J Hypertens. 1997, 15: 87-91. 10.1097/00004872-199715010-00009.CrossRefPubMed
51.
go back to reference Cifkov AAR, Nakov R, NovozAmsk AE, Hejl Z, Petrzílkova Z, Poledne R, Stávek P, Compagnone D: Evaluation of the effects of fixed combinations of sustained-release verapamil/trandolapril versus captopril/hydrochlorothiazide on metabolic and electrolyte parameters in patients with essential hypertension. J Hum Hypertens. 2000, 14: 347-354. 10.1038/sj.jhh.1001014.CrossRef Cifkov AAR, Nakov R, NovozAmsk AE, Hejl Z, Petrzílkova Z, Poledne R, Stávek P, Compagnone D: Evaluation of the effects of fixed combinations of sustained-release verapamil/trandolapril versus captopril/hydrochlorothiazide on metabolic and electrolyte parameters in patients with essential hypertension. J Hum Hypertens. 2000, 14: 347-354. 10.1038/sj.jhh.1001014.CrossRef
52.
go back to reference Malacco E, Piazza S, Carretta R, Di Somma S, Mugellini A, Bertocchi F, Palatini P: Comparison of benazepril-amlodipine and captopril-thiazide combinations in the management of mild-to-moderate hypertension. Int J Clin Pharmacol Ther. 2002, 40: 263-269.PubMed Malacco E, Piazza S, Carretta R, Di Somma S, Mugellini A, Bertocchi F, Palatini P: Comparison of benazepril-amlodipine and captopril-thiazide combinations in the management of mild-to-moderate hypertension. Int J Clin Pharmacol Ther. 2002, 40: 263-269.PubMed
53.
go back to reference Mugellini A, Dobovisek J, Planinc D, Cremonesi G, Fogari R: Efficacy and safety of delapril plus manidipine compared with enalapril plus hydrochlorthiazide in mild to moderate essential hypertension: results of a randomized trial. Clin Ther. 2004, 26: 1419-1426. 10.1016/j.clinthera.2004.09.018.CrossRefPubMed Mugellini A, Dobovisek J, Planinc D, Cremonesi G, Fogari R: Efficacy and safety of delapril plus manidipine compared with enalapril plus hydrochlorthiazide in mild to moderate essential hypertension: results of a randomized trial. Clin Ther. 2004, 26: 1419-1426. 10.1016/j.clinthera.2004.09.018.CrossRefPubMed
54.
go back to reference Middeke M, Richter WO, Schwandt P, Holzgreve H: The effects of antihypertensive combination therapy on lipid and glucose metabolism: hydrochlorothiazide plus sotalol vs. hydrochlorothiazide plus captopril. Int J Clin Pharmacol Ther. 1997, 35: 231-234.PubMed Middeke M, Richter WO, Schwandt P, Holzgreve H: The effects of antihypertensive combination therapy on lipid and glucose metabolism: hydrochlorothiazide plus sotalol vs. hydrochlorothiazide plus captopril. Int J Clin Pharmacol Ther. 1997, 35: 231-234.PubMed
55.
go back to reference Poulter NR, Wedel H, Dahlof B, Sever PS, Beevers DG, Caulfield M, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Ostergren J, Pocock S: Role of blood pressure and other variables in the differential cardiovascular event rates noted in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOTBPLA). Lancet. 2005, 366: 907-913. 10.1016/S0140-6736(05)67186-3.CrossRefPubMed Poulter NR, Wedel H, Dahlof B, Sever PS, Beevers DG, Caulfield M, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Ostergren J, Pocock S: Role of blood pressure and other variables in the differential cardiovascular event rates noted in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOTBPLA). Lancet. 2005, 366: 907-913. 10.1016/S0140-6736(05)67186-3.CrossRefPubMed
56.
go back to reference Bakris G, Molitch M, Hewkin A, Kipnes M, Sarafidis P, Fakouhi K, Bacher P, Sowers J, STAR Investigators: Differences in glucose tolerance between fixed-dose antihypertensive drug combinations in people with metabolic syndrome. Diabetes Care. 2006, 29: 2592-2597. 10.2337/dc06-1373.CrossRefPubMed Bakris G, Molitch M, Hewkin A, Kipnes M, Sarafidis P, Fakouhi K, Bacher P, Sowers J, STAR Investigators: Differences in glucose tolerance between fixed-dose antihypertensive drug combinations in people with metabolic syndrome. Diabetes Care. 2006, 29: 2592-2597. 10.2337/dc06-1373.CrossRefPubMed
57.
go back to reference Holzgreve H, Nakov R, Beck K, Janka HU: Antihypertensive therapy with verapamil SR plus trandolapril versus atenolol plus chlorthalidone on glycemic control. Am J Hypertens. 2003, 16: 381-386. 10.1016/S0895-7061(03)00062-1.CrossRefPubMed Holzgreve H, Nakov R, Beck K, Janka HU: Antihypertensive therapy with verapamil SR plus trandolapril versus atenolol plus chlorthalidone on glycemic control. Am J Hypertens. 2003, 16: 381-386. 10.1016/S0895-7061(03)00062-1.CrossRefPubMed
58.
go back to reference Breithaupt GR, Ogler K, Gerhardt G, Lehmann G, Notter T, Belz GG: Blood pressure and aortic elastic properties: verapamil SR/trandolapril compared to a metoprolol/hydrochlorothiazide combination therapy. Int J Clin Pharmacol Ther. 1998, 36: 425-431. Breithaupt GR, Ogler K, Gerhardt G, Lehmann G, Notter T, Belz GG: Blood pressure and aortic elastic properties: verapamil SR/trandolapril compared to a metoprolol/hydrochlorothiazide combination therapy. Int J Clin Pharmacol Ther. 1998, 36: 425-431.
59.
go back to reference Jamerson K, Weber MA, Bakris GL, Dahlof B, Pitt B, Shi V, Hester A, Gupte J, Gatlin M, Velazquez EJ, ACCOMPLISH Trial Investigators: Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med. 2008, 359: 2417-2428. 10.1056/NEJMoa0806182.CrossRefPubMed Jamerson K, Weber MA, Bakris GL, Dahlof B, Pitt B, Shi V, Hester A, Gupte J, Gatlin M, Velazquez EJ, ACCOMPLISH Trial Investigators: Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med. 2008, 359: 2417-2428. 10.1056/NEJMoa0806182.CrossRefPubMed
60.
go back to reference De la Sierra A, Gil-Extremera B, Calvo C, Campo C, García-Puig J, Márquez E, Oliván J, Roca CA, Sanz de Castro S, Pontes C, Delgadillo J: Comparison of the antihypertensive effects of the fixed dose combination enalapril 10 mg/nitrendipine 20 mg vs losartan 50 mg/hydrochlorothiazide 12.5 mg, assessed by 24-h ambulatory blood pressure monitoring, in essential hypertensive patients. J Hum Hypertens. 2004, 18: 215-22. 10.1038/sj.jhh.1001655.CrossRefPubMed De la Sierra A, Gil-Extremera B, Calvo C, Campo C, García-Puig J, Márquez E, Oliván J, Roca CA, Sanz de Castro S, Pontes C, Delgadillo J: Comparison of the antihypertensive effects of the fixed dose combination enalapril 10 mg/nitrendipine 20 mg vs losartan 50 mg/hydrochlorothiazide 12.5 mg, assessed by 24-h ambulatory blood pressure monitoring, in essential hypertensive patients. J Hum Hypertens. 2004, 18: 215-22. 10.1038/sj.jhh.1001655.CrossRefPubMed
61.
go back to reference Davis TM, Millns H, Stratton IM, Holman RR, Turner RC: Risk factors for stroke in type 2 diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS). Arch Intern Med. 1999, 159: 1097-1103. 10.1001/archinte.159.10.1097.CrossRefPubMed Davis TM, Millns H, Stratton IM, Holman RR, Turner RC: Risk factors for stroke in type 2 diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS). Arch Intern Med. 1999, 159: 1097-1103. 10.1001/archinte.159.10.1097.CrossRefPubMed
62.
go back to reference Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I, for the Collaborative Study Group: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001, 345: 851-860. 10.1056/NEJMoa011303.CrossRefPubMed Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I, for the Collaborative Study Group: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001, 345: 851-860. 10.1056/NEJMoa011303.CrossRefPubMed
63.
go back to reference Devabhaktuni M, Bangalore S: Fixed combination of amlodipine and atorvastatin in cardiovascular risk management: patient perspectives. Vasc Health Risk Manag. 2009, 5: 377-387.PubMedCentralPubMed Devabhaktuni M, Bangalore S: Fixed combination of amlodipine and atorvastatin in cardiovascular risk management: patient perspectives. Vasc Health Risk Manag. 2009, 5: 377-387.PubMedCentralPubMed
64.
go back to reference Miura Y, Yamamoto N, Tsunekawa S, Taguchi S, Eguchi Y, Ozaki N, Oiso Y: Replacement of valsartan and candesartan by telmisartan in hypertensive patients with type 2 diabetes. Diabetes Care. 2005, 28: 737-738. 10.2337/diacare.28.3.757.CrossRef Miura Y, Yamamoto N, Tsunekawa S, Taguchi S, Eguchi Y, Ozaki N, Oiso Y: Replacement of valsartan and candesartan by telmisartan in hypertensive patients with type 2 diabetes. Diabetes Care. 2005, 28: 737-738. 10.2337/diacare.28.3.757.CrossRef
65.
go back to reference Inoue T, Morooka T, Moroe K, Ikeda H, Node K: Effect of Telmisartan on Cholesterol Levels in Patients with Hypertension - Saga Telmisartan Aggressive Research (STAR). Horm Metab Res. 2007, 39: 372-376. 10.1055/s-2007-976544.CrossRefPubMed Inoue T, Morooka T, Moroe K, Ikeda H, Node K: Effect of Telmisartan on Cholesterol Levels in Patients with Hypertension - Saga Telmisartan Aggressive Research (STAR). Horm Metab Res. 2007, 39: 372-376. 10.1055/s-2007-976544.CrossRefPubMed
66.
go back to reference Schupp M, Clemenz M, Gineste R, Witt H, Janke J, Helleboid S, Hennuyer N, Ruiz P, Unger T, Staels B, Kintscher U: Molecular characterization of new selective peroxisome proliferators-activated receptor γ modulators with angiotensine receptor blocking activity. Diabetes. 2005, 54: 3442-3452. 10.2337/diabetes.54.12.3442.CrossRefPubMed Schupp M, Clemenz M, Gineste R, Witt H, Janke J, Helleboid S, Hennuyer N, Ruiz P, Unger T, Staels B, Kintscher U: Molecular characterization of new selective peroxisome proliferators-activated receptor γ modulators with angiotensine receptor blocking activity. Diabetes. 2005, 54: 3442-3452. 10.2337/diabetes.54.12.3442.CrossRefPubMed
67.
go back to reference Garg R, Yusuf S: Overview of randomized trials of angiotensin-converting enzyme inhibitors on the mortality and morbidity in patients with heart failure. JAMA. 1995, 18: 1450-1455. 10.1001/jama.273.18.1450.CrossRef Garg R, Yusuf S: Overview of randomized trials of angiotensin-converting enzyme inhibitors on the mortality and morbidity in patients with heart failure. JAMA. 1995, 18: 1450-1455. 10.1001/jama.273.18.1450.CrossRef
68.
go back to reference Krum H: Beta-blockers in heart failure. The 'new wave' of clinical trials. Drugs. 1999, 58: 203-210. 10.2165/00003495-199958020-00001.CrossRefPubMed Krum H: Beta-blockers in heart failure. The 'new wave' of clinical trials. Drugs. 1999, 58: 203-210. 10.2165/00003495-199958020-00001.CrossRefPubMed
69.
go back to reference Rouleau JL, Roecker EB, Tendera M, Mohacsi P, Krum H, Katus HA, Fowler MB, Coats AJ, Castaigne A, Scherhag A, Holcslaw TL, Packer M: Carvedilol Prospective Randomized Cumulative Survival Study Group. Influence of pretreatment systolic blood pressure on the effect of carvedilol in patients with severe chronic heart failure: the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) study. J Am Coll Cardiol. 2004, 43: 1423-1429. 10.1016/j.jacc.2003.11.037.CrossRefPubMed Rouleau JL, Roecker EB, Tendera M, Mohacsi P, Krum H, Katus HA, Fowler MB, Coats AJ, Castaigne A, Scherhag A, Holcslaw TL, Packer M: Carvedilol Prospective Randomized Cumulative Survival Study Group. Influence of pretreatment systolic blood pressure on the effect of carvedilol in patients with severe chronic heart failure: the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) study. J Am Coll Cardiol. 2004, 43: 1423-1429. 10.1016/j.jacc.2003.11.037.CrossRefPubMed
70.
go back to reference McMurray JJ, Ostergren J, Swedberg K, Granger CB, Held P, Michelson EL, Olofsson B, Yusuf S, Pfeffer MA: CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet. 2003, 362: 767-771. 10.1016/S0140-6736(03)14283-3.CrossRefPubMed McMurray JJ, Ostergren J, Swedberg K, Granger CB, Held P, Michelson EL, Olofsson B, Yusuf S, Pfeffer MA: CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet. 2003, 362: 767-771. 10.1016/S0140-6736(03)14283-3.CrossRefPubMed
71.
go back to reference Mann JF, Schmieder RE, McQueen M, Dyal L, Schumacher H, Pogue J, Wang X, Maggioni A, Budaj A, Chaithiraphan S, Dickstein K, Keltai M, Metsärinne K, Oto A, Parkhomenko A, Piegas LS, Svendsen TL, Teo KK, Yusuf S: Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): A multicentre, randomised, double-blind, controlled trial. Lancet. 2008, 372: 547-553. 10.1016/S0140-6736(08)61236-2.CrossRefPubMed Mann JF, Schmieder RE, McQueen M, Dyal L, Schumacher H, Pogue J, Wang X, Maggioni A, Budaj A, Chaithiraphan S, Dickstein K, Keltai M, Metsärinne K, Oto A, Parkhomenko A, Piegas LS, Svendsen TL, Teo KK, Yusuf S: Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): A multicentre, randomised, double-blind, controlled trial. Lancet. 2008, 372: 547-553. 10.1016/S0140-6736(08)61236-2.CrossRefPubMed
72.
go back to reference Zamboli P, De Nicola L, Minutolo R, Bertino V, Catapano F, Conte G: Management of hypertension in chronic kidney disease. Curr Hypertens Rep. 2006, 8: 497-501. 10.1007/s11906-006-0029-4.CrossRefPubMed Zamboli P, De Nicola L, Minutolo R, Bertino V, Catapano F, Conte G: Management of hypertension in chronic kidney disease. Curr Hypertens Rep. 2006, 8: 497-501. 10.1007/s11906-006-0029-4.CrossRefPubMed
73.
go back to reference Ong KL, Cheung BM, Man YB, Lam KS, Lau CP: Prevalence, awareness, treatment, and control of hypertension among United States adults 1999-2004. Hypertension. 2007, 49: 69-75. 10.1161/01.HYP.0000252676.46043.18.CrossRefPubMed Ong KL, Cheung BM, Man YB, Lam KS, Lau CP: Prevalence, awareness, treatment, and control of hypertension among United States adults 1999-2004. Hypertension. 2007, 49: 69-75. 10.1161/01.HYP.0000252676.46043.18.CrossRefPubMed
74.
go back to reference Insua JT, Sacks HS, Lau TS, Lau J, Reitman D, Pagano D, Chalmers TC: Drug Treatment of Hypertension in the Elderly: A Meta-Analysis. Ann Intern Med. 1994, 121: 355-362.CrossRefPubMed Insua JT, Sacks HS, Lau TS, Lau J, Reitman D, Pagano D, Chalmers TC: Drug Treatment of Hypertension in the Elderly: A Meta-Analysis. Ann Intern Med. 1994, 121: 355-362.CrossRefPubMed
75.
go back to reference Chaudhry SI, Krumholz HM, Foody JM: Systolic hypertension in older persons. JAMA. 2004, 292: 1074-1080. 10.1001/jama.292.9.1074.CrossRefPubMed Chaudhry SI, Krumholz HM, Foody JM: Systolic hypertension in older persons. JAMA. 2004, 292: 1074-1080. 10.1001/jama.292.9.1074.CrossRefPubMed
76.
go back to reference Zeglin MA, Pacos J, Bisognano JD: Hypertension in the very elderly: Brief review of management. Cardiol J. 2009, 16: 379-385.PubMed Zeglin MA, Pacos J, Bisognano JD: Hypertension in the very elderly: Brief review of management. Cardiol J. 2009, 16: 379-385.PubMed
77.
go back to reference Yoder SR, Thornburg LL, Bisognano JD: Hypertension in pregnancy and women of childbearing age. Am J Med. 2009, 122: 890-895. 10.1016/j.amjmed.2009.03.036.CrossRefPubMed Yoder SR, Thornburg LL, Bisognano JD: Hypertension in pregnancy and women of childbearing age. Am J Med. 2009, 122: 890-895. 10.1016/j.amjmed.2009.03.036.CrossRefPubMed
78.
go back to reference Sleight P, Pouleur H, Zannad F: Benefits, challenges, and registerability of the polypill. Eur Heart J. 2006, 27: 1651-1656. 10.1093/eurheartj/ehi841.CrossRefPubMed Sleight P, Pouleur H, Zannad F: Benefits, challenges, and registerability of the polypill. Eur Heart J. 2006, 27: 1651-1656. 10.1093/eurheartj/ehi841.CrossRefPubMed
79.
go back to reference Stirban AO, Tschoepe D: Should we be more aggressive in the therapy against cardiovascular risk factors? Should we prescribe statin and aspirin for every diabetic patient, or is it time for a polypill?. Diabetes Care. 2008, 31 (Suppl 2): 226-228. 10.2337/dc08-s254.CrossRef Stirban AO, Tschoepe D: Should we be more aggressive in the therapy against cardiovascular risk factors? Should we prescribe statin and aspirin for every diabetic patient, or is it time for a polypill?. Diabetes Care. 2008, 31 (Suppl 2): 226-228. 10.2337/dc08-s254.CrossRef
Metadata
Title
Combination therapy in hypertension: An update
Authors
Sanjay Kalra
Bharti Kalra
Navneet Agrawal
Publication date
01-12-2010
Publisher
BioMed Central
Published in
Diabetology & Metabolic Syndrome / Issue 1/2010
Electronic ISSN: 1758-5996
DOI
https://doi.org/10.1186/1758-5996-2-44

Other articles of this Issue 1/2010

Diabetology & Metabolic Syndrome 1/2010 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.